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Abstract
The mitogen-activated protein kinase (MAPK) phos-
phatase-1 (MKP-1) belongs to the MAPK cascades 
which are central to cell proliferation and apoptosis. 
The carcinogenic role of MKP-1 has been reported in 
many types of cancer but it has rarely been investigated 
in breast cancer. The present study was designed to 
evaluate the MKP-1 mRNA expression and its possible 
regulation by methylation of MKP-1 promoter in the 
model of several breast cancer cell lines and tissues 
as well as controls. Our data demonstrate MKP-1 
mRNA  expression  significantly  decreased  in  five 
breast cancer cell lines compared to breast controls (P＜
0.01). Using the methylation-specific PCR (MSP) anal-
ysis, the unmethylated reaction (U) is dominant in both 
normal cell lines and benign breast tumors (100% vs. 
86.2%), whereas the methylated reaction (M) is domi-
nant in both breast cancer cell lines and invasive breast 
tumors (100% vs. 57.2%). In terms of methylation ratio 
(M/M+U), methylation level in MKP-1 promoter is sig-
nificantly higher in the invasive breast tumor tissues 
(n = 152) than in benign breast tumor tissues (n = 29) 
(P ＜ 0.0001). Assessing the methylation ratio of the 
promoter of MKP-1 gene to diagnose the breast malig-
nancy (invasive vs. benign), the area under the re-
ceiver-operating characteristic (ROC) curve was 0.809 
(95% CI: 0.711-0.906, P ＜ 0.001). The best perform-
ance for this prediction has a sensitivity of 76.32% and 
a specificity of 82.76% at the cutoff value of 0.38. Taken 
together, we firstly demonstrated that the promoter 
methylation of MKP-1 gene is a potential breast cancer MKP-1 promoter methylation in breast cancer    357
Figure 1. The mRNA expression of MKP-1 gene in several breast can-
cer cell lines. Normal breast cell lines (M10) and breast cancer cell lines 
(MCF7, T47D, MDA-MB-231, SKBR3, and BT474) were included. The 
quantity of cDNA in each preparation was estimated by real time 
RT-PCR in the reference of the internal control actin gene. Experiments 
were repeated in triplicate. *P ＜ 0.01.
biomarker for breast malignancy.
Keywords: biological markers; breast neoplasms; 
DNA methylation; DUSP1 protein, human; epigenesis, 
genetic 
Introduction
Breast cancer remains a common malignancy among 
women. The high incidence and prevalence of 
breast cancer represents a major public health 
problem and understanding the molecular features 
of breast cancer has been a central target in bio-
medical research. Among the many signaling path-
ways central to cell proliferation and apoptosis are 
the mitogen-activated protein kinase (MAPK) cas-
cades (Whitmarsh and Davis, 1999). The mi-
togen-activated protein kinase (MAPK) phospha-
tase-1 (MKP-1), also known as the dual-specificity 
phosphatase 1 (DUSP1), mediates the dephos-
phorylation and inactivation of MAPKs in in-
sulin-responsive tissues. The actions of MKP-1 may 
play an important role in the maintenance of meta-
bolic homeostasis (Roth Flach and Bennett, 2010a, 
2010b). 
    Recently, accumulating evidence has shown that 
the MKP-1 is also involved in carcinogenesis. 
Some different types of cancers including prostate 
(Rauhala et al., 2005), liver (Loda et al., 1996), re-
nal (Mizuno et al., 2004), and urothelial (Shimada et 
al., 2007) cancers showed decreased MKP-1 
mRNA or protein expression. For example, the 
MKP-1 mRNA in hormone-refractory prostate carcino-
mas was expressed at a lower level than in benign 
prostate hyperplasia or untreated prostate carcino-
mas (Rauhala et al., 2005). This down-regulation 
of MKP-1 is regarded as an early event in prostate 
carcinogenesis. In liver cancer, most (80%) hep-
atocellular carcinomas expressed low levels of 
mRNA based on in situ hybridization analysis 
(Loda et al., 1996). In renal cancer, both Caki-1 
and KU 20–01 cell lines showed decreased MKP-1 
protein expression (Mizuno et al., 2004). In ur-
othelial cancer, MKP-1 protein showed lower ex-
pression in high-grade/invasive phenotype than in 
low-grade/noninvasive in the urothelial cancer cell 
lines (Shimada et al., 2007). In contrast, primary 
gastric adenocarcinomas were found to express 
higher MKP-1 protein than normal gastric tissues 
(Bang et al., 1998). Hence, the MKP-1 expression 
in tumors relative to normal tissue is either still con-
troversial or shows a cancer type-dependent ex-
pression manner (Boutros et al., 2008), i.e., in-
crease or decrease. However, the relative MKP-1 
expression in breast cancer compared to normal 
tissues has not been adequately studied.
    Alterations in DNA methylation are a hallmark of 
human cancer, especially occurring at CpG islands 
within the promoter regions of genes (Issa, 2004; 
Cairns, 2007). There is accumulating evidence to 
show that abnormal DNA methylation occurs in 
early carcinogenesis (Esteller et al., 2001; Shih et 
al., 2010) and may have an important role in the 
early detection and prognosis monitoring of cancer 
(Baylin and Ohm, 2006). For breast cancer, altered 
methylation in malignant is higher than that of 
benign breast tissue (Zhu et al., 2010), especially 
on the promoters of genes (Brooks et al., 2009). 
The CpG methylation signatures have been 
reported to be the potential diagnostic, prognostic, 
and predictive tools for breast cancer (Jovanovic et 
al., 2010; Parrella, 2010). The methylation analysis 
also improves early breast cancer detection (Caldeira 
et al., 2006; Noetzel et al., 2008; Henneges et al., 
2009; Seniski et al., 2009; Veeck et al., 2009; Wu 
et al., 2010; Zurita et al., 2010; Suijkerbuijk et al., 
2011). However, the relationship between MKP-1 
gene expression and methylation in breast cancer 
remains unclear.
        The aim of this study was to investigate the 
mRNA expression and methylation status for 
MKP-1 gene of breast cancer tissues and cell lines 
compared to those of the normal tissues and cell 
lines. The potential use of methylation status for 
MKP-1 gene as the breast cancer biomarker was 
also evaluated.
Results
MKP-1 mRNA levels in breast normal and cancer cell 
lines 
Using the real time RT-PCR analysis, actin and 358    Exp. Mol. Med. Vol. 44(5), 356-362, 2012
Figure 2. MSP of the promoter of 
MKP-1 gene in several breast cell 
lines (normal vs. cancer) and breast 
tissues (benign vs. invasive tumor). 
(A) Demonstration of MSP in a 
normal breast cell lines and several 
benign breast tissues. (B) Demon-
stration of MSP in several breast 
cancer cell lines and invasive breast 
tumor tissues. (C) Methylation status 
in all breast cell lines (normal and 
cancer) and tissues (benign and 
invasive) tested. M, methylated 
(155-bp); U, unmethylated (158-bp).
MKP-1 mRNA expressions were examined in all 6 
cell lines. After adjustment, the MKP-1 fold activation 
in normal breast cell line M10 is regarded as 
control. In Figure 1, the tested breast cancer cell 
lines (MCF7, T47D, MDA-MB-231, SKBR3, and 
BT474) show the fold activation of 0.894 ± 0.003, 
0.118 ±0.008, 0.437 ±0.020, 0.164 ±0.014, 0.586
±0.026 (mean ± SD; n = 3), respectively. It shows 
significantly reduction for MKP-1 mRNA expressions 
in these five breast cancer cell lines compared to 
normal control (P ＜0.01).
MSP of the promoter of MKP-1 gene in breast normal 
and cancer cell lines
The possible reasons for the breast cancer cell 
lines expressing lower MKP-1 mRNA level than 
that of breast normal cell line (Figure 1) were 
examined in terms of the methylation status for 
MKP-1. Using the MSP assay, the breast normal 
cell line (M10) shows the unmethylated (U) band 
only (the upper part in Figure 2A and the left side in 
Figure 2C) without the detectable methylated (M) 
band. In contrast, the breast cancer cell lines 
(MCF7, T47D, MDA-MB-231, SKBR3, and BT474) 
show the methylated (M) bands only (the upper 
part in Figure 2B and the left side in Figure 2C). 
Regarding the methylation ratio (for band intensity) 
as described in Materials and methods, the methy-
lation results in breast normal and cancer cell lines 
are 0 (n =1) and 1 (n = 7), respectively.
MSP of the promoter of MKP-1 gene in breast normal 
and cancer tissues
Using the MSP, we also examined the methylation 
status of MKP-1 gene in several breast normal and 
cancer tissues. Several representative MSP results 
are demonstrated in Figures 2A and 2B. In Figure 
2A (bottom), three breast benign tissues (NB01, 
Fb01, and N01) show unmethylated reaction (U) 
only. In contrast, the breast cancer (invasive) 
tissues such as T01, T02, T03, T04, and T05 show 
both methylated (M) and unmethylated (U) reaction 
(bottom in Figure 2B). 
    Actually, MSP analysis of the MKP-1 gene was 
carried out with DNA extracted from 29 benign and 
152 invasive breast tumor tissues (left side, Figure 
2C). The presence of U vs. M of MSP in the benign 
and the invasive breast tumor tissues is 25 vs. 4 
and 65 vs. 87, respectively. Of these, the U is dom-
inant (86.2%) in benign breast tumors whereas the 
M is dominant (57.2%) in invasive breast tumors. 
Similarly, the methylation ratios for the benign (n =
29) and invasive (n =152) breast tumor tissues 
show 0.24 ±0.24 and 0.52 ±0.26, respectively. MKP-1 promoter methylation in breast cancer    359
Characteristic Patient no. % Mean* ± SD
ANOVA 
(P value)
LN meta
  Negative
  Positive
Grade
  I
  II
  III
ER
  Negative
  Positive
PR
  Negative
  Positive
HER2
  Negative
  Positive
Stage
  I
  II
  III + IV
Recurrence
  Absent
  Present
  85
  67
    9
  93
  44
  50
102
  67
  85
101
  50
  68
  52
  32
137
  15
55.9
44.1
  6.2
63.7
30.1
33.9
67.1
44.1
55.9
66.9
33.1
44.7
34.2
21.1
90.1
  9.9
0.51 ± 0.29
0.54 ± 0.22
0.55 ± 0.28
0.52 ± 0.27
0.52 ± 0.23
0.54 ± 0.26
0.52 ± 0.26
0.53 ± 0.27
0.52 ± 0.25
0.51 ± 0.25
0.56 ± 0.28
0.49 ± 0.28
0.54 ± 0.24
0.57 ± 0.24
0.52 ± 0.26
0.59 ± 0.25
0.515
0.893
0.615
0.751
0.283
0.280
0.310
*Methylation ratio, intensity of M/intensity of U + M. LN meta, lymph node 
metastasis; SD, standard deviation; ER, estrogen receptor; PR, proges-
terone receptor. 
Table 1. Correlation of methylation ratio for MKP-1 gene with 
clinicopathological characteristic in breast cancer
Sensitivity (%) Specificity (%) Cutoff (methylation ratio)
67.76
76.32
78.95
88.16
86.21
82.76
75.86
68.97
0.43
0.38
0.35
0.24
Table  2. Different cutoffs and their relative sensitivities and 
specificities of methylation ratios of the promoter of MKP-1 gene
for assessing the malignancy of breast cancer
Figure 3. Receiver-operating characteristic (ROC) analysis for malig-
nancy prediction of breast cancer based on the mathylation ratio for 
MKP-1 gene. AUC, area under curve.
The methylation ratio of invasive breast tumor tis-
sues is significantly higher than that of benign 
breast tumor tissues (P ＜0.0001).
Methylation of the promoter of MKP-1 gene and 
clinicopathological characteristic in breast cancer
As shown in Table 1, the differences of methylation 
ratios in lymph node metastasis (LN meta), grades, 
estrogen receptor (ER), progesterone receptor 
(PR), human epidermal growth factor receptor 2 
(HER2), stages, and recurrence to breast cancer 
are not significant.
Diagnostic performance of MKP-1 promoter 
methylation for malignancy in breast cancer
ROC curves were used to assess the feasibility of 
using methylation ratio of the promoter of MKP-1 
gene as a diagnostic tool to detect the malignancy 
of breast cancer. The area under the ROC curve 
assessing methylation ratio of the promoter of 
MKP-1 gene serving as the diagnostic tool to detect 
the malignancy (invasive vs. benign) of breast 
cancer was 0.809 (95% CI: 0.711-0.906, P ＜ 
0.001) (Figure 3).
    In Table 2, the sensitivities and specificities of 
the methylation ratio of MKP-1 promoter assessing 
the malignancy of breast cancer for different cutoff 
values are presented, i.e., 67.76 vs. 86.21, 76.32 
vs. 82.21, 78.95 vs. 75.86, and 88.16 vs. 68.97 for 
the cutoff values of 0.43, 0.38, 0.35, and 0.24, 
respectively. The methylation ratio of MKP-1 promoter 
assessing the malignancy of breast cancer showed 
the best performance with a sensitivity of 76.32% 
and a specificity of 82.76% at the cutoff value 0.38. 
Discussion
The identification of genes that change the promoter 
methylation status might help to discover new 
biomarkers for tumor diagnosis and prognosis. For 
example, hypermethylation of RASSF1A, HIN-1, 
RAR-β, Cyclin D2, and Twist genes has been 
reported in early diagnosis for breast cancer 
(Fackler et al., 2003). In this study, we focused on 
breast cancer and examined the mRNA expression 
of MKP-1 gene as well as its promoter methylation 
status.
    Since breast cancer is a heterogeneous disease 
with several subtypes (Perou et al., 2000), many 
subtypes of breast cancer cell lines were included 
to measure its mRNA expression in our study. The 360    Exp. Mol. Med. Vol. 44(5), 356-362, 2012
mRNA expression of MKP-1 gene was down-regu-
lated in five subtypes of breast cancer cell lines 
compared to controls (Figure 1), which is con-
sistent with many other types of cancer (Loda et 
al., 1996; Mizuno et al., 2004; Rauhala et al., 2005; 
Shimada et al., 2007).
    Among  these  studies,  the  mRNA  expression 
level of MKP-1 gene in prostate cancer was 
reported to be down-regulated, and its regulation 
involved the DNA methylation (Rauhala et al., 
2005). Similarly, we found that the methylation 
status of MKP-1 gene in terms of methylation ratio 
was significantly higher in the normal breast cell 
line and 29 benign breast tumors than in five 
breast cancer cell lines and 152 invasive breast 
tumors (Figure 2). The ROC curve (AUC=0.809) 
shows that the methyation ratio of the promoter of 
MKP-1 gene has high sensitivity and specificity for 
discriminating between malignant breast tumor and 
benign breast tumor. With the increase of the 
methylation ratio the promoter of MKP-1 gene, the 
specificity for predicting the malignancy of breast 
cancer increases (Table 2).
    However, the methyation ratio of the promoter of 
MKP-1 gene may not be an effective prediction in-
dicator for discrimination of several clinicopatho-
logical characteristics of breast cancer as listed in 
Table 1. For example, the area under the ROC 
curve assessing methylation ratio of the promoter 
of MKP-1 gene as the diagnostic tool to detect the 
recurrence (absent vs. present) of breast cancer 
was 0.634 (95% confidence interval (CI): 0.502-0.765; 
P =0.087).
        In breast cancer cell lines (Figure 2B), un-
methylated portion was not detected. However, the 
MPK-1 gene expressed differently (10-90% of con-
trol) without complete inhibition of gene expression. 
These results suggested that the methylation of 
the promoter of MPK-1 gene in terms of our MSP 
result cannot fully explain the downregulation of 
MPK-1 gene. This finding may partly be due to the 
MSP (Lee et al., 2004; Park et al., 2005) only fo-
cusing on part of the possible methylation sites 
within the designed primers. Therefore, the methyl-
ation status of this gene needs further assay by bi-
sulfite sequencing (Park et al., 2007) or py-
rosequencing (Marsh, 2007; Shames et al., 2007) 
of the cell lines to provide the detailed methylation 
profile for the promoter of MKP-1 gene. Moreover, 
the role of methylation in modulating the MKP-1 
gene expression is not clearly addressed in this 
study. Methylation as a possible mechanism of 
gene silencing of MKP-1 gene would be answered 
when it is investigated by treatment of breast can-
cer cell lines with the methyltransferase inhibitor, 
such as demethylating agent, 5-azadeoxycytidine 
(Park et al., 2005, 2007). We cannot exclude the 
possibility that other non-methylation factors may 
be involved in the regulation of MKP-1 gene 
expression. In our study, we demonstrated that 
methylation level of MKP-1 is a potential diagnostic 
tool for assessing the malignancy. However, the re-
lationship between gene expression of MKP-1 gene 
and the methylation status have not been ad-
dressed, and further investigation is required.
    In conclusion, the methylation level is significantly 
higher in malignant breast cancer than benign 
breast cancer, and it is a potential diagnostic tool 
for assessing malignancy in breast cancer.
Methods
DNA, breast tumor tissues, and cell lines
Genomic DNA was obtained from breast cell lines, primary 
tumors, and normal tissue. The benign (n=29) and in-
vasive (n=152) breast tumor tissues were kindly provided 
by the Cancer Center of Kaohsiung Medical University 
Hospital approved by the IRB in Kaohsiung Medical 
University. Human breast cancer cell lines MCF7, SKBR3, 
MDA-MB-453, T47D, BT474 and MDA-MB-231 were ob-
tained from the National Centre for Cell Science, Pune, 
India and the American Type Culture Collection (ATCC), 
respectively. T47D cell line was maintained in RPMI 1640, 
others cells were grown as monolayer cultures in Dulbecco's 
modified Eagle’s Medium/Ham’s Nutrient Mixture F12 
(DMEM/F12) (Sigma Aldrich, Bangalore, India) supple-
mented with 10% fetal bovine serum. Normal mammary 
epithelial cell H184B5F5/M10 (M10) was purchased from 
the Bioresource Collection and Research Center (Hsinchu, 
Taiwan). These cells were maintained in culture in 
Dulbecco's modified Eagle's medium (DMEM) containing 
10% fetal bovine serum at 37
oC in a humidified atmos-
phere of 95% air and 5% carbon dioxide. Genomic DNA 
was extracted using the QIAamp DNA Mini Kit (Qiagen, 
Valencia, CA) according to the manufacturer's instructions.
RNA extraction and real time RT-PCR
Total RNA was extracted by Trizol reagents (Invitrogen, 
corp.) in accordance with the manufacturer’s manual. Total 
RNA (2 μg) was reverse-transcribed using oligo-dT primer 
and Superscript III reverse transcriptase (Invitrogen, USA). 
Quantitative real time PCR was performed using iQ SYBR 
Green Supermix (Bio-Rad) (Yen et al., 2009) in an iCycler 
MyiQ single color real-time PCR detection system (Bio- Rad 
Laboratories, Hercules, CA). The mRNA levels of MKP-1 and 
controls were further validated using real time-PCR. MKP-1 
primers were based on NCBI/UniSTS:156846/GDB:371394 
(found by e-PCR in sequences from Homo sapiens) and 
human actin primers for the internal control were described 
previously (Hall et al., 2008). Primer sequences are in-
cluded in Supplemental Data Table S1. 
    The fold activation for MKP-1 mRNA expression was an-
alyzed using the -ΔΔCt method (Livak and Schmittgen 
2001), where the Ct (threshold cycle) value of an MKP-1 MKP-1 promoter methylation in breast cancer    361
gene was subtracted from the Ct value of a reference 
housekeeping gene, actin. After real time PCR, melting 
curve analyses and gel electrophoreses were performed to 
ensure the specificity of the quantitative RT-PCR reactions 
(Chang et al., 2008; Yen et al., 2009).
Methylation-specific PCR (MSP) (Herman et al., 1996)
DNA was modified with 1 μg of genomic DNA using a 
CpGenomet DNA modification kit (Chemicon, Temecula, 
CA) (Shieh et al., 2005) according to the manufacturer’s 
protocol. Modified DNA was resuspended in TE buffer stor-
ed at -80
oC. Modified DNA was amplified in a total volume 
of 10 μL solution containing 1x PCR buffer, 1.5 mM MgCl2, 
200 ng of each primer, 0.2 mM of each dNTP and 1 U 
Platinum Taq Polymerase (Invitrogen). Primer sequences 
for MSP are included in Supplemental Data Table S1. The 
PCR conditions used were same for both PCRs and are as 
follows: 5 min of initial denaturation at 94
oC, 35 amplification 
cycles (denaturation for 30 s at 94
oC, annealing for 30 s at 
54
oC, and extension for 30 s at 72
oC), and final extension 
for 10 min at 72
oC. PCR products were then loaded and 
electrophoresed on 2% agarose gels, stained with ethi-
dium bromide and visualized under UV illumination.
Methylation ratio
The methylation status was detected by MSP and the in-
tensities of methylated (M) and unmethylated (U) bands 
were individually quantified with the aid of the Gel Pro 
Analyzer ver. 4. The relative amount of methylation (Yan et 
al., 2006) in the sample was slightly modified and calcu-
lated using the following formula: methylation ratio=M/(M+
U), where M and U indicated their band intensities meas-
ured by the gel scanning.
Statistics
Data analyses were performed using the SPSS 13.0 
package. Comparisons of the means of each case group to 
that of the control group were performed by t test. 
Receiver-operating characteristic (ROC) curves (Chang et 
al., 2002, 2007) were used to assess the methylation ratio 
as diagnostic tools for detecting breast cancer. The area 
under the ROC curve was a measure of the overall ability 
of a diagnostic test with multiple cutoffs of methylation ratio 
to distinguish between breast cancer patients and controls.
Supplemental data
Supplemental Data include a table and can be found with 
this article online at http://e-emm.or.kr/article/article_files/ 
SP-44-5-06.pdf.
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